Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC

Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical for the survival of cancer cells, thereby inhibiting tumor growth.

In February 2004, the U.S. Food and Drug Administration (FDA) approved pemetrexed disodium in combination with cisplatin to treat a rare cancer, malignant pleural mesothelioma. Malignant pleural mesothelioma is a rare lung pleural cancer. Pemetrexed disodium can interfere with cancer cell replication and further promote tumor cell apoptosis by blocking the unique mechanism of 3 key enzymes of cancer cell metabolism.

This treatment plan is a synergistic inhibitory effect of three targets, which is superior to the single-target treatment plan using cisplatin in the past. At the same time, by supplementing folic acid and vitamins, the toxic and side effects can be effectively controlled and the patient's tolerance can be enhanced. In August 2004, the FDA approved pemetrexed disodium as a second-line treatment for locally advanced lung cancer or metastatic non-small cell lung cancer with fast approval. In December 2005, pemetrexed disodium, a patented drug of Eli Lilly, was launched in China and was approved for the treatment of malignant pleural mesothelioma.

According to the statistics of the world's best-selling drugs, the sales of pemetrexed in 2005 were 463 million US dollars, and in 2014 it reached a peak of 2.792 billion US dollars. Sales in 2017 were $2.063 billion. Its global sales declined after 2015 due to patent expiry.

In December 2005, Eli Lilly's pemetrexed disodium was launched in China. With the addition of domestic imitation products, the market competition was fierce.

In the first three quarters of 2021, domestic sales of pemetrexed disodium reached 3.679 billion, a year-on-year increase of 4.19%. The drug sales market is crowded by generic drug companies, accounting for 78.49%. However, affected by volume purchases, only original research drugs and products that have passed the consistency evaluation of generic drugs can enter the centralized procurement process. Therefore, Sichuan Huiyu Pharma and Eli Lilly are more competitive than other companies, accounting for 42.55% and 21.51% respectively.

Huateng Pharma, as a leading pharmaceutical intermediates supplier in China, can provide CAS NO.137281-39-1, CAS NO.165049-28-5, CAS NO.1118-89-4, CAS NO.155405-80-4 and CAS NO.3140-73-6 from lab to commercial scale, which can be used as Pemetrexed disodium intermediates. Also, we can provide CDMO services to meet your requirements, combining a high level of competencies, equipment and quality.

Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China
Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China
Email: sales@huatengusa.com
Website: https://us.huatengsci.com/
Zip code: 410205
Telephone: +86 731 89916275
Fax: +86 0731-82251112-818

Huateng Pharma is a global provider in contract development and manufacturing for intermediates.  With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.

This release was published on openPR.